Masimo’s board considered other potential partners before determining Danaher was an “ideal fit,” executives at the patient ...

In this week’s edition of InnovationRx, we look at Jennifer Doudna’s $1 billion plan to bring Crispr gene editing to the real ...

Danaher has struck an almost $10bn deal to buy patient monitoring company Masimo, two years after an activist investor ...

Danaher Corporation (NYSE:DHR) announced it has entered into a definitive agreement to acquire Masimo Corporation (NASDAQ: ...

Feb 16 (Reuters) - Life sciences firm Danaher is closing in on a nearly $10 billion deal to acquire pulse oximeter maker ...

Danaher Corp. is snapping up patient monitoring medtech Masimo in a $9.9 billion deal aimed at strengthening its diagnostics ...

Masimo Corporation (Nasdaq: MASI) ("Masimo"), a leading global medical innovator, today announced that it has entered into a definitive agreement pursuant to which Danaher Corporation (NYSE: DHR) ...

Danaher is acquiring Masimo for $9.9B, integrating its patient monitoring innovations to enhance diagnostics and drive growth in acute care settings.

Diagnostics business unit News of the agreement sent Masimo’s Nasdaq-listed stock price up in value by more than 30 per cent, with the $180-per-share purchase price last achieved just under a year ago ...

Masimo held a 23.1% share of the US pulse oximetry systems market in 2025, as per GlobalData analysis.

Danaher Corporation DHR said Tuesday it has agreed to acquire Masimo Corporation MASI for $180.00 per share in cash, ...

Danaher Corporation, a global science and technology company, has entered into a definitive agreement to acquire Masimo Corporation, a specialty diagnostics provider of pulse oximetry and ...